Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Abstract
Context Bladder cancer has become a common cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder cancer. Evidence acquisition Global bladder cancer incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder cancer statistics geographically or over time. Patient summary The main risk factor for bladder cancer is tobacco smoking. The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The epidemiology of bladder cancer varies by region, with tobacco smoking, occupational exposures (e.g., aromatic amines), and arsenic contamination of drinking water among the putative causes in industrialized countries.
“The epidemiology of bladder cancer varies by region, with tobacco smoking, occupational exposures (e.g., aromatic amines), and arsenic contamination of drinking water among the putative causes in industrialized countries.159,160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
Diverging bladder cancer incidence trends have been observed by sex since the 1990s, with rates tending to decrease or stabilize in men but increase among women in certain European countries (e.g., in Spain, the Netherlands, Germany, and Belarus).
“Diverging bladder cancer incidence trends have been observed by sex since the 1990s, with rates tending to decrease or stabilize in men but increase among women in certain European countries (e.g., in Spain, the Netherlands, Germany, and Belarus).160,162,163”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
Comparing trends in bladder cancer mortality rates may be more suitable for assessing progress in disease control than comparing incidence trends.
“comparing trends in bladder cancer mortality rates may be more suitable for assessing progress in disease control.160,166”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
There may be artifactual changes in bladder cancer incidence because of differences in coding and registration practice concerning inclusion or otherwise of noninvasive carcinomas.
“Of note, there may be artifactual changes in incidence because of differences in coding and registration practice concerning inclusion or otherwise of noninvasive carcinomas.160,166,167”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
Increases in bladder cancer mortality rates have been reported among men in Thailand, Israel, and Slovakia and among women in Thailand, Japan, Croatia, and Poland.
“increases in mortality rates have also been reported among men in Thailand, Israel, and Slovakia and among women in Thailand, Japan, Croatia, and Poland.160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766 · see citing works
Self-citationCancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485 · see citing works
The United Nations Development Programme
Oestreich, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780190637347.003.0003 · Cited by 4,936 · see citing works
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932 · see citing works
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Babjuk, M. M., Andreas Böhle, E., Burger, M., Čapoun, O., Cohen, D. L., Compérat, É., Hernández, V., KAASINEN, E. S., Palou, J., Morgan Rouprêt, A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.041 · Cited by 2,240 · see citing works
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G. M., Grossman, H. B., Herr, H. W., Karakiewicz, P. I., Kassouf, W., Kiemeney, L. A. L. M., Vecchia, C. L., Shariat, S. F., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,169 · see citing works
Steinmann, P., Keiser, J., Bos, R., Tanner, M., & Utzinger, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70521-7 · Cited by 2,146 · see citing works
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576 · see citing works
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R. C., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,271 · see citing works
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174 · see citing works
Association Between Smoking and Risk of Bladder Cancer Among Men and Women
Freedman, N. D. (2011) · JAMA · doi:10.1001/jama.2011.1142 · Cited by 1,144 · see citing works
Global status report on noncommunicable diseases
Chan, M. (2010) · Cited by 1,065 · see citing works
Cancer mortality for selected sites in 24 countries
栗原, 登., & 瀬木, 三. (1960) · Medical Entomology and Zoology · Cited by 880 · see citing works
Preventable Exposures Associated With Human Cancers
Cogliano, V. J., Baan, R. A., Straíf, K., Grosse, Y., Secretan, B., Ghissassi, F. E., Bouvard, V., Benbrahim‐Tallaa, L., Guha, N., Freeman, C., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr483 · Cited by 826 · see citing works
Karim‐Kos, H. E., de Vries, E., Soerjomataram, I., Lemmens, V. E. P. P., Siesling, S., & Coebergh, J. W. W. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.12.015 · Cited by 750 · see citing works
Self-citationBray, F., Ferlay, J., Laversanne, M., Brewster, D., Mbalawa, C. G., Kohler, B., Piñeros, M., Steliarova‐Foucher, E., Swaminathan, R., Antoni, S., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29670 · Cited by 645 · see citing works
Self-citationCumberbatch, M. G. K., Rota, M., Catto, J. W. F., & Vecchia, C. L. (2015) · European Urology · doi:10.1016/j.eururo.2015.06.042 · Cited by 450 · see citing works
Part I: Cancer in Indigenous Africans—burden, distribution, and trends
Parkin, D. M., Sitas, F., Chirenje, M. Z., Stein, L., Abratt, R. P., & Wabinga, H. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70175-x · Cited by 427 · see citing works
Gakis, G., Efstathiou, J. A., Lerner, S. P., Cookson, M. S., Keegan, K. A., Guru, K. A., Shipley, W. U., Heidenreich, A., Schoenberg, M., Sagaloswky, A. I., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.08.009 · Cited by 422 · see citing works
Fifty-Year Study of Lung and Bladder Cancer Mortality in Chile Related to Arsenic in Drinking Water
Marshall, G., Catterina Ferreccio, R., Yuan, Y., Bates, M., Steinmaus, C., Selvin, S., Liaw, J., & Smith, A. H. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm004 · Cited by 363 · see citing works
The global burden of urinary bladder cancer
Parkin, D. M. (2008) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/03008880802285032 · Cited by 357 · see citing works
Economic Burden of Bladder Cancer Across the European Union
Leal, J., Luengo-Fernández, R., Sullivan, R. J., & Witjes, J. A. (2015) · European Urology · doi:10.1016/j.eururo.2015.10.024 · Cited by 332 · see citing works
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320 · see citing works
Kamat, A. M., Hegarty, P. K., Gee, J., Clark, P. E., Svatek, R. S., Hegarty, N. J., Shariat, S. F., Xylinas, E. N., Schmitz‐Dräger, B. J., Lotan, Y., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.09.057 · Cited by 264 · see citing works
Occupational cancer burden in Great Britain
Rushton, L., Hutchings, S. J., Fortunato, L., Young, C., EVANS, G. S., Brown, T. P., Bevan, R. J., Slack, R. J., Holmes, P., Bagga, S., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.112 · Cited by 256 · see citing works
International rules for multiple primary cancers (ICD-0 third edition)
Working Group Report&NA; (2005) · European Journal of Cancer Prevention · doi:10.1097/00008469-200508000-00002 · Cited by 215 · see citing works
Drinking Water Arsenic in Northern Chile: High Cancer Risks 40 Years after Exposure Cessation
Steinmaus, C., Catterina Ferreccio, R., Romo, J. A., Yan Yuan, A., Cortés, S., Marshall, G., Moore, L. E., Balmes, J. R., Liaw, J., Golden, T. R., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1190 · Cited by 205 · see citing works
Park, S., Jee, S. H., Shin, H., Park, E. H., Shin, A., Jung, K., Hwang, S.-S., Cha, E. S., Yun, Y. H., Park, S. K., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-406 · Cited by 161 · see citing works
The changing patterns of bladder cancer in Egypt over the past 26 years
Felix, A. S., Soliman, A. S., Khaled, H. M., Zaghloul, M. S., Banerjee, M., El-Baradie, M. M., El-Kalawy, M., Abd-Elsayed, A. A., Ismail, K., Hablas, A., et al. (2008) · Cancer Causes & Control · doi:10.1007/s10552-007-9104-7 · Cited by 159 · see citing works
Agudo, A., Bonet, C., Travier, N., Gonzalez, C. A., Vineis, P., Bueno-de-Mesquita, H. B., Trichopoulos, D., Boffetta, P., Clavel‐Chapelon, F., Boutron‐Ruault, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0183 · Cited by 159 · see citing works
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, D., Bell, S., Sund, R., Hartikainen, S. A., Tuomilehto, J., Pukkala, E., Keskimäki, I., Badrick, E., Renehan, A. G., et al. (2015) · Diabetologia · doi:10.1007/s00125-014-3456-9 · Cited by 158 · see citing works
Nielsen, M. E., Smith, A. B., Meyer, A., Kuo, T., Tyree, S., Kim, W. Y., Milowsky, M. I., Pruthi, R. S., & Millikan, R. C. (2014) · Cancer · doi:10.1002/cncr.28397 · Cited by 149 · see citing works
Janssen, F., & Kunst, A. E. (2004) · PubMed · Cited by 142 · see citing works
Drope, J. M., & Schluger, N. W. (2018) · Cited by 138 · see citing works
The proportion of cancer attributable to occupational exposures
Purdue, M. P., Hutchings, S. J., Rushton, L., & Silverman, D. T. (2015) · Annals of Epidemiology · doi:10.1016/j.annepidem.2014.11.009 · Cited by 127 · see citing works
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis
Turner, R. M., Kwok, C. S., Chen‐Turner, C., Maduakor, C. A., Singh, S., & Loke, Y. K. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12306 · Cited by 126 · see citing works
An assessment of GLOBOCAN methods for deriving national estimates of cancer incidence
Antoni, S., Soerjomataram, I., Møller, B., Bray, F., & Ferlay, J. (2016) · Bulletin of the World Health Organization · doi:10.2471/blt.15.164384 · Cited by 115 · see citing works
Self-citationBilharziasis and bladder cancer: a time trend analysis of 9843 patients.
Gouda, I., Mokhtar, N. M., Bilal, D., El-Bolkainy, T., & El-Bolkainy, N. (2007) · PubMed · Cited by 107 · see citing works
Salem, H. K., & Mahfouz, S. (2011) · Urology · doi:10.1016/j.urology.2011.08.072 · Cited by 99 · see citing works
Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5
Marcos‐Gragera, R., Mallone, S., Kiemeney, L. A. L. M., Vilardell, L., Malats, N., Allory, Y., Sant, M., Hackl, M., Zielonke, N., Oberaigner, W., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.028 · Cited by 87 · see citing works
Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and Perspectives
Larré, S., Catto, J. W. F., Cookson, M. S., Messing, E. M., Shariat, S. F., Soloway, M. S., Svatek, R. S., Lotan, Y., Zlotta, A. R., & Grossman, H. B. (2013) · European Urology · doi:10.1016/j.eururo.2012.12.062 · Cited by 81 · see citing works
Jacobs, B. L., Montgomery, J. S., Zhang, Y., Skolarus, T. A., Weizer, A. Z., & Hollenbeck, B. K. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.08.011 · Cited by 70 · see citing works
Schistosomiasis in Malawi: a systematic review
Makaula, P., Sadalaki, J. R., Muula, A. S., Kayuni, S. A., Jemu, S., & Bloch, P. (2014) · Parasites & Vectors · doi:10.1186/s13071-014-0570-y · Cited by 58 · see citing works
Tetrachloroethylene Exposure and Bladder Cancer Risk: A Meta-Analysis of Dry-Cleaning-Worker Studies
Vlaanderen, J. J., Straíf, K., Ruder, A. M., Blair, A. E., Hansen, J., Lynge, E., Charbotel, B., LOOMIS, D. P., Kauppinen, T. P., Kyyrönen, P., et al. (2014) · Environmental Health Perspectives · doi:10.1289/ehp.1307055 · Cited by 51 · see citing works
Smoking and Cancers of Bladder and Pancreas: Risks and Temporal Trends 2
Moolgavkar, S. H., & Stevens, R. G. (1981) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/67.1.15 · Cited by 48 · see citing works
Carcinogenicity of some drugs and herbal products
Grosse, Y., LOOMIS, D. P., Secretan, B., Ghissassi, F. E., Bouvard, V., Benbrahim‐Tallaa, L., Guha, N., Baan, R. A., Mattock, H., & Straíf, K. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70329-2 · Cited by 35 · see citing works
N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort
Pesch, B., Gawrych, K., Rabstein, S., Weiss, T., Casjens, S., Rihs, H.-P., Ding, H., Angerer, J., Illig, T., Klopp, N., et al. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0119-t · Cited by 35 · see citing works
Trends in principal cancer risk factors in Spain
Regidor, E., Gutiérrez-Fisac, J. L., Ichaso, M. D. L. S., & Fernández, E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq086 · Cited by 29 · see citing works
Smoking and Cancers of Bladder and Pancreas: Risks and Temporal Trends
Moolgavkar, S. H., & Steven, R. G. (1982) · The Journal of Urology · doi:10.1016/s0022-5347(17)54070-7 · Cited by 25 · see citing works
Antonova, O., Toncheva, D. I., & Grigorov, E. E. (2016) · PubMed · Cited by 14 · see citing works
WHY HAS THE SURVIVAL OF PATIENTS WITH BLADDER CANCER NOT IMPROVED?
Malmström, P. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07308.x · Cited by 12 · see citing works
Neumann, A., Weill, A., Ricordeau, P., Fagot, J., Alla, F., & Allemand, H. (2012) · Revue d Épidémiologie et de Santé Publique · doi:10.1016/j.respe.2011.12.100 · Cited by 11 · see citing works
Flagged first, then by citations
3 of the 55 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · see citing works
Self-citationBray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064 · see citing works
“160,166,167 Because these cancers often represent a large proportion of all bladder cancers 168 and are commonly associated with reasonably favorable survival, comparing trends in bladder cancer mortality rates may be more suitable for assessing progress in disease control.”
BackgroundSelf-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D. M., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C. T., ELIAS, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,587 · see citing works
Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
Cumberbatch, M. G. K., Jubber, I., Black, P. C., Esperto, F., Figueroa, J. D., Kamat, A. M., Kiemeney, L. A. L. M., Lotan, Y., Pang, K. H., Silverman, D. T., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.001 · Cited by 822 · see citing works
Self-citationŞanlı, Ö., Dobruch, J. T., Knowles, M. A., Burger, M., Mehrdad Alemozaffar, A., Nielsen, M. E., & Lotan, Y. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.22 · Cited by 819 · see citing works
Chen, Z., Zhou, L., Liu, L., Hou, Y., Xiong, M., Yang, Y., Hu, J., & Chen, K. (2020) · Nature Communications · doi:10.1038/s41467-020-18916-5 · Cited by 694 · see citing works
Panebianco, V., Narumi, Y., Altun, E., Bochner, B. H., Efstathiou, J. A., Hafeez, S., Huddart, R. A., Kennish, S. J., Lerner, S. P., Montironi, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.04.029 · Cited by 663 · see citing works
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
Flaig, T. W., Spiess, P. E., Abern, M., Bangs, R., Bangs, R., Begovic, J., Brown, J., Buyyounouski, M. K., Chan, K., Chang, P. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0011 · Cited by 630 · see citing works
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 604 · see citing works
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J. Y., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 580 · see citing works
CircHIPK3 sponges miR‐558 to suppress heparanase expression in bladder cancer cells
Li, Y., Zheng, F., Xiao, X., Xie, F., Tao, D., Huang, C., Liu, D., Wang, M., Wang, L., Zeng, F., et al. (2017) · EMBO Reports · doi:10.15252/embr.201643581 · Cited by 559 · see citing works
Yang, C., Yuan, W., Yang, X. F., Peng, L., Wang, J., Han, J., Tao, J., Li, P., Yang, H., Lv, Q., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0771-7 · Cited by 516 · see citing works
Arsenic exposure: A public health problem leading to several cancers
Lara, I. P., Castillo, M. M., Quintana-Pérez, J. C., Arellano-Mendoza, M. G., Cach, F. T., Valenzuela, O. L., García-Montalvo, E. A., & Hernández‐Zavala, A. (2019) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2019.104539 · Cited by 480 · see citing works
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
Pettenati, C., & Ingersoll, M. A. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0055-4 · Cited by 459 · see citing works
Zhong, Z., Huang, M., Lv, M., He, Y., Duan, C., Zhang, L., & Chen, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.027 · Cited by 450 · see citing works
Current best practice for bladder cancer: a narrative review of diagnostics and treatments
Compérat, É., Amin, M. B., Cathomas, R. L., Choudhury, A., Santis, M. D., Kamat, A. M., Stenzl, A., Thoeny, H. C., & Witjes, J. A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01188-6 · Cited by 441 · see citing works
Bladder Cancer: Current Challenges and Future Directions
Dobruch, J. T., & Oszczudłowski, M. (2021) · Medicina · doi:10.3390/medicina57080749 · Cited by 424 · see citing works
A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer
Wu, S., Zheng, J., Li, Y., Yu, H., Shi, S., Xie, W., Liu, H., Su, Y., Huang, J., & Lin, T. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1510 · Cited by 399 · see citing works
van Hoogstraten, L. M. C., Vrieling, A., van der Heijden, A. G., Kogevinas, M., Richters, A., & Kiemeney, L. A. L. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00744-3 · Cited by 392 · see citing works
Epidemiology, Screening, and Prevention of Bladder Cancer
Lobo, N., Afferi, L., Moschini, M., Mostafid, H. A., Porten, S. P., Psutka, S. P., Gupta, S., Smith, A. B., Williams, S. B., & Lotan, Y. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.10.003 · Cited by 382 · see citing works
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
Bellmunt, J., Powles, T., & Vogelzang, N. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.007 · Cited by 374 · see citing works
Global Burden of Urologic Cancers, 1990–2013
Dy, G. W., Gore, J. L., Forouzanfar, M. H., Naghavi, M., & Fitzmaurice, C. (2016) · European Urology · doi:10.1016/j.eururo.2016.10.008 · Cited by 373 · see citing works
Sex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P. I., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 369 · see citing works
Progress in cancer mortality, incidence, and survival: a global overview
Santucci, C., Carioli, G., Bertuccio, P., Malvezzi, M., Pastorino, U., Boffetta, P., Negri, E., Bosetti, C., & Vecchia, C. L. (2020) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000594 · Cited by 341 · see citing works
Lu, Q., Liu, T., Feng, H., Yang, R., Zhao, X., Chen, W., Jiang, B., Qin, H., Guo, X., Liu, M., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1040-0 · Cited by 312 · see citing works
Wong, M. C. S., Fung, F. D. H., Leung, C., Cheung, W. W. L., Goggins, W. B., & Ng, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-19199-z · Cited by 308 · see citing works
Lin, T., Zhao, X., Zhao, S., Yu, H., Cao, W., Chen, W., Wei, H., & Guo, H. (2018) · Theranostics · doi:10.7150/thno.22465 · Cited by 305 · see citing works
Targeting 3D Bladder Cancer Spheroids with Urease-Powered Nanomotors
Hortelão, A. C., Carrascosa, R., Murillo-Cremaes, N., Patiño, T., & Sánchez, S. (2019) · ACS Nano · doi:10.1021/acsnano.8b06610 · Cited by 287 · see citing works
Bladder Cancer, Version 3.2024
Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Buyyounouski, M. K., Chan, K., Chang, S. S., Chang, P. J., Friedlander, T. W., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0024 · Cited by 286 · see citing works
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
Antonio Lopez-beltran, B., Cimadamore, A., Blanca, A., Massari, F., Vau, N., Scarpelli, M., Liang Cheng, C., & Montironi, R. (2021) · Cancers · doi:10.3390/cancers13010131 · Cited by 283 · see citing works
Natural products: An upcoming therapeutic approach to cancer
Dutta, S., Mahalanobish, S., Saha, S., Ghosh, S., & Sil, P. C. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.012 · Cited by 264 · see citing works
Teoh, J. Y.-C., Huang, J., Ko, W. Y.-K., Lok, V., Choi, P., Ng, C.-F., Sengupta, S., Mostafid, H., Kamat, A. M., Black, P. C., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.09.006 · Cited by 257 · see citing works
The potential role of N7-methylguanosine (m7G) in cancer
Luo, Y., Yao, Y., Wu, P. S., Zi, X., Sun, N., & He, J. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01285-5 · Cited by 257 · see citing works
Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid
Ceci, C., Lacal, P. M., Tentori, L., Martino, M. G. D., Miano, R., & Graziani, G. (2018) · Nutrients · doi:10.3390/nu10111756 · Cited by 254 · see citing works
Management of metastatic bladder cancer
Nadal, R., & Joaquim Bellmunt, B. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.002 · Cited by 249 · see citing works
Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect
Han, J., Gu, X., Li, Y., & Wu, Q. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110393 · Cited by 237 · see citing works
Xie, B., Lin, J., Chen, X., Zhou, X., Zhang, Y., Fan, M., Xiang, J., He, N., Hu, Z., & Wang, F. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01856-1 · Cited by 221 · see citing works
The multifaceted immune regulation of bladder cancer
Schneider, A. K., Chevalier, M. F., & Derré, L. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0226-y · Cited by 222 · see citing works
Ni, Z., Sun, P., Zheng, J., Wu, M., Yang, C., Cheng, M., Yin, M., Cui, C., Wang, G., Yuan, L., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1323 · Cited by 219 · see citing works
Taber, A., Christensen, E., Lamy, P., Nordentoft, I., Prip, F., Lindskrog, S. V., Birkenkamp‐Demtröder, K., Okholm, T. L. H., Knudsen, M., Pedersen, J. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18640-0 · Cited by 211 · see citing works
Pfannstiel, C., Strissel, P. L., Chiappinelli, K. B., Sikic, D., Wach, S., Wirtz, R. M., Wullweber, A., Taubert, H. W., Breyer, J., Otto, W., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0758 · Cited by 210 · see citing works
Recent Progress of Supramolecular Chemotherapy Based on Host–Guest Interactions
Yan, M., Wu, S., Wang, Y., Liang, M., Wang, M., Hu, W., Yu, G., Mao, Z., Huang, F., & Zhou, J. (2023) · Advanced Materials · doi:10.1002/adma.202304249 · Cited by 214 · see citing works
Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression
Su, H.-W., Tao, T., Yang, Z., Kang, X., Zhang, X., Kang, D., Wu, S., & Li, C. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0951-0 · Cited by 210 · see citing works
Gu, C., Wang, Z., Zhou, N., Li, G., Kou, Y., Luo, Y., Wang, Y., Yang, J., & Tian, F. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1084-1 · Cited by 205 · see citing works
The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040
Zhang, Y., Rumgay, H., Li, M., Yu, H., Pan, H., & Ni, J. (2023) · Journal of Global Health · doi:10.7189/jogh.13.04109 · Cited by 212 · see citing works
[i]In-vivo[/i] Raman spectroscopy: from basics to applications
Cordero, E., Latka, I., Matthäus, C., Schie, I. W., & Popp, J. (2018) · Journal of Biomedical Optics · doi:10.1117/1.jbo.23.7.071210 · Cited by 196 · see citing works
Jin, H., Ying, X., Que, B., Wang, X., Chao, Y., Zhang, H., Yuan, Z., Qi, D., Lin, S., Wang, M., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.068 · Cited by 195 · see citing works
Witjes, J. A., Babjuk, M., Joaquim Bellmunt, B., Bruins, H. M., de Reijke, T. M., Santis, M. D., Gillessen, S., James, N. D., MacLennan, S., Palou, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.09.035 · Cited by 194 · see citing works
Urease-powered nanobots for radionuclide bladder cancer therapy
Simó, C., Serra-Casablancas, M., Hortelão, A. C., Carlo, V. D., Guallar-Garrido, S., Plaza‐García, S., Rabanal, R. M., Ramos‐Cabrer, P., Yagüe, B., Aguado, L., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01577-y · Cited by 202 · see citing works
The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing
Nieuwenhuizen, N. E., Kulkarni, P. S., Shaligram, U. S., Cotton, M. F., Rentsch, C. A., Eisele, B., Grode, L., & Kaufmann, S. H. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01147 · Cited by 190 · see citing works
METTL1‐m7G‐EGFR/EFEMP1 axis promotes the bladder cancer development
Ying, X., Liu, B., Yuan, Z., Huang, Y., Chen, C., Xu, J., Zhang, H., Qi, D., Yang, S., Lin, S., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.675 · Cited by 188 · see citing works
Liu, H., Bi, J., Dong, W., Yang, M., Shi, J., Jiang, N., Lin, T., & Huang, J. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0908-8 · Cited by 186 · see citing works
Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine
Xue, C., Chu, Q., Zheng, Q., Jiang, S., Bao, Z., Su, Y., Lü, J., & Li, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01003-0 · Cited by 186 · see citing works
Trihalomethanes in Drinking Water and Bladder Cancer Burden in the European Union
Evlampidou, I., Font-Ribera, L., Rojas-Rueda, D., Gracia-Lavedan, E., Costet, N., Pearce, N., Vineis, P., Jaakkola, J. J. K., Delloye, F., Makris, K. C., et al. (2020) · Environmental Health Perspectives · doi:10.1289/ehp4495 · Cited by 178 · see citing works
Dong, W., Bi, J., Liu, H., Yan, D., He, Q., Zhou, Q., Wang, Q., Xie, R., Su, Y., Yang, M., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1025-z · Cited by 179 · see citing works
Arsenic toxicity: sources, pathophysiology and mechanism
Ganie, S. Y., Javaid, D., Hajam, Y. A., & Reshi, M. S. (2023) · Toxicology Research · doi:10.1093/toxres/tfad111 · Cited by 178 · see citing works
Wei, W., Sun, J., Zhang, H., Xiao, X., Huang, C., Wang, L., Zhong, H., Jiang, Y., Zhang, X., & Jiang, G. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1518 · Cited by 177 · see citing works
Woerl, A.-C., Eckstein, M., Geiger, J., Wagner, D., Daher, T., Stenzel, P., Fernandez, A., Hartmann, A., Wand, M., Roth, W., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.023 · Cited by 176 · see citing works
Horwich, A., Babjuk, M., Joaquim Bellmunt, B., Bruins, H. M., de Reijke, T. M., Santis, M. D., Gillessen, S., James, N. D., MacLennan, S., Palou, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz296 · Cited by 175 · see citing works
European cancer mortality predictions for the year 2020 with a focus on prostate cancer
Carioli, G., Bertuccio, P., Boffetta, P., Levi, F., Vecchia, C. L., Negri, E., & Malvezzi, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.009 · Cited by 171 · see citing works
Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis
Zhang, Y., Luo, G., Li, M., Guo, P., Xiao, Y., Ji, H., & Hao, Y. (2019) · BMC Cancer · doi:10.1186/s12885-019-6139-6 · Cited by 169 · see citing works
Wu, S., Zheng, J., Li, Y., Wu, Z., Shi, S., Huang, M. X., Yu, H., Dong, W., Huang, J., & Lin, T. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.07.029 · Cited by 168 · see citing works
Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention
Abbaoui, B., Lucas, C. R., Riedl, K. M., Clinton, S. K., & Mortazavi, A. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800079 · Cited by 165 · see citing works
Katanoda, K., Hori, M., Saito, E., Shibata, A., Ito, Y., Minami, T., Ikeda, S., Suzuki, T., & Matsuda, T. (2021) · Journal of Epidemiology · doi:10.2188/jea.je20200416 · Cited by 164 · see citing works
Emerging function and potential diagnostic value of circular RNAs in cancer
Cui, X., Wang, J., Guo, Z., Li, M., Li, M., Liu, S., Liu, H., Li, W., Yin, X., Tao, J., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0877-y · Cited by 163 · see citing works
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
Felsenstein, K. M., & Theodorescu, D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.179 · Cited by 159 · see citing works
Pioglitazone and bladder cancer risk: a systematic review and meta‐analysis
Tang, H., Shi, W., Fu, S., Wang, T., Zhai, S., Song, Y., & Han, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1354 · Cited by 157 · see citing works
CircRNA-Cdr1as Exerts Anti-Oncogenic Functions in Bladder Cancer by Sponging MicroRNA-135a
Li, P., Yang, X. F., Yuan, W., Yang, C., Zhang, X., Han, J., Wang, J., Deng, X., Yang, H., Li, P., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489208 · Cited by 156 · see citing works
Epidemiology, aetiology and screening of bladder cancer
party, O. B. O. T. E. Y. A. U. C. W., Cumberbatch, M. G. K., & Noon, A. P. (2019) · Translational Andrology and Urology · doi:10.21037/tau.2018.09.11 · Cited by 148 · see citing works
FTO modifies the m6A level of MALAT and promotes bladder cancer progression
Tao, L., Mu, X., Chen, H., Jin, D., Zhang, R., Zhao, Y., Fan, J., Cao, M., & Zhou, Z. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.310 · Cited by 151 · see citing works
Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review
Fonteyne, V., Ost, P., Joaquim Bellmunt, B., Droz, J. P., Mongiat-Artus, P., Inman, B. A., Paillaud, É., Fred Saad, C., & Ploussard, G. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.019 · Cited by 145 · see citing works
Defining cisplatin eligibility in patients with muscle-invasive bladder cancer
Jiang, D., Gupta, S., Kitchlu, A., Meraz-Muñoz, A., North, S. A., Alimohamed, N. S., Blais, N., & Sridhar, S. S. (2021) · Nature Reviews Urology · doi:10.1038/s41585-020-00404-6 · Cited by 144 · see citing works
Malek-Esfandiari, Z., Rezvani‐Noghani, A., Sohrabi, T., Mokaberi, P., Amiri‐Tehranizadeh, Z., & Chamani, J. (2023) · Journal of Fluorescence · doi:10.1007/s10895-023-03169-4 · Cited by 144 · see citing works
Air pollution exposure and bladder, kidney and urinary tract cancer risk: A systematic review
Sakhvidi, M. J. Z., Lequy, É., Goldberg, M., & Jacquemin, B. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.115328 · Cited by 139 · see citing works
Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer
Thomsen, M. B. H., Nordentoft, I., Lamy, P., Vang, S., Reinert, L. S., Mapendano, C. K., Høyer, S., Orntoft, T. F., Jensen, J. B., & Dyrskjøt, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-11291-0 · Cited by 135 · see citing works
The emerging role of circRNAs and their clinical significance in human cancers
Qian, L., Yu, S., Chen, Z., Meng, Z., Huang, S., & Wang, P. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.002 · Cited by 136 · see citing works
Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis
Liu, F., Zhang, H., Xie, F., Tao, D., Xiao, X., Huang, C., Wang, M., Gu, C., Zhang, X., & Jiang, G. (2019) · Oncogene · doi:10.1038/s41388-019-1092-z · Cited by 134 · see citing works
FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance
Jing, W., Wang, G., Cui, Z., Xiong, G., Jiang, X., Li, Y., Li, W., Han, B., Chen, S., & Shi, B. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2362 · Cited by 134 · see citing works
Zhan, Y., Chen, Z., Li, Y., He, A., He, S., Gong, Y., Li, X., & Zhou, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0921-1 · Cited by 133 · see citing works
Yuan, W., Zhou, R., Wang, J., Han, J., Yang, X. F., Yu, H., Lu, H., Zhang, X., Li, P., Tao, J., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12523 · Cited by 132 · see citing works
Enhancing the Delivery of Chemotherapeutics: Role of Biodegradable Polymeric Nanoparticles
Ahlawat, J., Henrı́quez, G., & Narayan, M. (2018) · Molecules · doi:10.3390/molecules23092157 · Cited by 131 · see citing works
Soerjomataram, I., Cabasag, C., Bardot, A., Fidler-Benaoudia, M. M., Miranda-Filho, A., Ferlay, J., Parkin, D. M., Ranganathan, R., Piñeros, M., Znaor, A., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00704-5 · Cited by 128 · see citing works
Self-citationBladder cancer-related microbiota: examining differences in urine and tissue samples
Mansour, B., Monyók, Á., Makra, N., Gajdács, M., Vadnay, I., Ligeti, B., Juhász, J., Szabó, D., & Ostorházi, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-67443-2 · Cited by 128 · see citing works
lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA‐150
Luo, H., Xu, C., Le, W., Ge, B., & Wang, T. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28622 · Cited by 127 · see citing works
The evolving genomic landscape of urothelial carcinoma
Glaser, A. P., Fantini, D., Shilatifard, A., Schaeffer, E. M., & Meeks, J. J. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.11 · Cited by 124 · see citing works
Zhan, Y., Chen, Z., He, S., Gong, Y., He, A., Li, Y., Zhang, L., Zhang, X., Fang, D., Li, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1143-7 · Cited by 126 · see citing works
Liu, Z., Zhou, Q., Wang, Z., Zhang, H., Zeng, H., Huang, Q., Chen, Y., Jiang, W., Lin, Z., Qu, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000978 · Cited by 125 · see citing works
Circ-BPTF promotes bladder cancer progression and recurrence through the miR-31-5p/RAB27A axis
Bi, J., Liu, H., Cai, Z., Dong, W., Jiang, N., Yang, M., Huang, J., & Lin, T. (2018) · Aging · doi:10.18632/aging.101520 · Cited by 124 · see citing works
USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway
He, H., Yi, L., Zhang, B., Yan, B., Xiao, M., Ren, J., Zi, D., Zhu, L. W., Zhong, Z., Zhao, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.54442 · Cited by 124 · see citing works
Yang, Y., Wang, J., Huang, W., Wan, G., Xia, M., Chen, D., Zhang, Y., Wang, Y., Guo, F., Tan, J., et al. (2022) · Advanced Materials · doi:10.1002/adma.202203224 · Cited by 120 · see citing works
Davis, R. M., Kiss, B. M., Trivedi, D. R., Metzner, T. J., Liao, J. C., & Gambhir, S. S. (2018) · ACS Nano · doi:10.1021/acsnano.8b03217 · Cited by 119 · see citing works
de Oliveira, E. C. M., Caixeta, E. S., Santos, V. S. V., & Pereira, B. B. (2021) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2021.1898504 · Cited by 116 · see citing works
Wang, H., Mei, Y., Luo, C., Huang, Q., Wang, Z., Lu, G.-M., Qin, L., Sun, Z., Huang, C.-W., Yang, Z.-W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4796 · Cited by 116 · see citing works
Guarino, A., Polini, C., Forte, G., Favieri, F., Boncompagni, I., & Casagrande, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010209 · Cited by 106 · see citing works
Shan, G., Zhou, X., Gu, J., Zhou, D., Cheng, W., Wu, H., Wang, Y., Tang, T., & Wang, X. (2021) · Cellular Oncology · doi:10.1007/s13402-020-00500-0 · Cited by 114 · see citing works
Yu, L., Li, Z., Mei, H., Li, W., Chen, D., Liu, L., Zhang, Z., Sun, Y., Song, F., Chen, W., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1248 · Cited by 113 · see citing works
Vartolomei, M. D., Porav-Hodade, D., Ferro, M., Mathiéu, R., Abufaraj, M. M., Foerster, B., Kimura, S., & Shariat, S. F. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.05.014 · Cited by 113 · see citing works
Safiri, S., Kolahi, A., & Naghavi, M. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2020-004128 · Cited by 113 · see citing works
Lin, Y., Lin, J., Wen, S.-I., Yang, S.-C., Tsai, T., Chen, H., Chou, K., & Hwang, T. I. (2017) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2017.01.004 · Cited by 108 · see citing works
Knapp, D. W., Dhawan, D., Ramos, J. A., Ratliff, T. L., Cresswell, G. M., Utturkar, S. M., Sommer, B. C., Fulkerson, C. M., & Hahn, N. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01493 · Cited by 108 · see citing works
- Authors
- Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F.
- Affiliations
- Centre international de recherche sur le cancer (FR)
- American Cancer Society (US)
- Corresponding author
- Bray, Freddie
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 71
- Issue
- 1
- Pages
- 96-108
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2473162054
- Cited by
- 2,514
- References
- 55
- Citations by year
- 2026: 79 · 2025: 165 · 2024: 248 · 2023: 244 · 2022: 314 · 2021: 414 · 2020: 400 · 2019: 306 · 2018: 225 · 2017: 102 · 2016: 11 · 2015: 1
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Urology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Keywords
- bladder cancer, cancer incidence, cancer mortality, incidence trends, sex differences, smoking, Schistosoma haematobium, etiology, global cancer statistics
- MeSH terms
- Urinary Bladder Neoplasms, Female, Humans, Male, Registries, Risk Factors, Smoking, Global Health, Incidence, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
